Article
Widespread molecular alterations present in stage I non-small cell lung carcinoma fail to predict tumor recurrence.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Jan 2003
Baksh Fabien K, Dacic Sanja, Finkelstein Sydney D, Swalsky Patricia A, Raja Siva, Sasatomi Eizaburo, Luketich James D, Fernando Hiran C, Yousem Samuel A
Abstract excerpt
Stage I non-small cell carcinoma (NSCLC) of the lung is typically treated with surgery alone, but with a 30 to 40% recurrence rate. Prognostic factors to stratify these patients into high- and low-risk groups would be of significant clinical value, but published data are conflicting. We studied 39 Stage I NSCLC treated with resection alone, followed for a minimum of 5 years, and divided into recurrent (RC) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.